|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 6-K filed Aug 28, 2009. Contract
Revenue
Contract revenue increased 36% to $12.5 million in the
first half of 2009 from $9.2 million for the same period in
2008. The increase was primarily related to a licence fee of
$7.7 million due from Acorda as a result of Acorda entering
into an agreement with Biogen Idec to develop and commercialise
Fampridine-SR in all territories outside the United States.
Acorda paid this licence fee to us in July 2009.
This excerpt taken from the ELN 6-K filed Mar 30, 2009. Contract
Revenue
Contract revenue increased 2% to $17.6 million in 2008 from
$17.2 million in 2007. Contract revenue consists of
research revenue and milestones arising from R&D activities
we perform on behalf of third parties or technology licensing.
The fluctuation in contract revenue was primarily due to the
level of external R&D projects and the timing of when the
milestones are earned.
This excerpt taken from the ELN 20-F filed Feb 26, 2009. Contract
revenue
Contract revenue was $20.0 million in 2008,
$21.5 million in 2007 and $19.0 million in 2006.
Contract revenue consists of research revenue and milestones
arising from R&D activities we perform on behalf of third
parties or technology licensing. The fluctuations between years
in contract revenue were primarily due to the level of external
R&D projects and the timing of when the milestones are
earned.
This excerpt taken from the ELN 6-K filed Mar 31, 2008. Contract
Revenue
Contract revenue consists of research revenue and milestones
arising from R&D activities we perform on behalf of third
parties. Total contract revenue increased 66% to
$24.5 million in 2007 from $14.8 million in 2006. The
increase in contract revenue within both of our
Biopharmaceuticals and EDT businesses were primarily due to the
timing of milestone receipts.
This excerpt taken from the ELN 20-F filed Feb 28, 2008. Contract
Revenue
Contract revenue consists of research revenue and milestones
arising from R&D activities we perform on behalf of third
parties or technology licensing. The fluctuations between years
in contract revenue within both of our Biopharmaceuticals and
EDT businesses were primarily due to the timing of milestone
receipts.
This excerpt taken from the ELN 6-K filed Mar 30, 2007. Contract
Revenue
Contract revenue, which consists of research revenue and
milestones arising from R&D activities we perform on behalf
of third parties, totalled $14.8 million in 2006, compared
to $15.3 million in 2005, a decrease of 3%. The decrease in
contract revenue was primarily due to the timing of milestone
receipts and a reduction in R&D activities for third parties.
This excerpt taken from the ELN 20-F filed Feb 28, 2007. Contract
Revenue
The decrease in contract revenue of 58% in 2005 is principally
due to a reduction in research revenue and milestones arising
from R&D activities we perform on behalf of third parties.
The reduction resulted from, among other things, the timing of
milestone receipts, the completion of transitional R&D
activities related to certain divested products, and the
suspension of activity related to Sonata.
This excerpt taken from the ELN 6-K filed Mar 31, 2006. Contract Revenue
Contract revenue, which comprises research revenue and
milestones, totalled $15.3 million in 2005, compared to
$73.0 million in 2004, a decrease of 79%. The decrease is
due to a reduction in research revenue and milestones arising
from R&D activities we perform on behalf of third parties.
The reduction resulted from, among other things, the timing of
milestone receipts, principally related to milestone payments of
$14.0 million received in 2004 (2005: $Nil) for Tysabri
from Biogen Idec, a reduction in R&D activities, and the
suspension of activity related to Sonata.
44 Elan Corporation, plc 2005 Annual Report
Table of Contents
This excerpt taken from the ELN 20-F filed Mar 30, 2006. Contract
Revenue
Included in amortized fees for 2003 is $35.2 million
related to the business ventures that were restructured or
terminated as part of our recovery plan. There were no revenues
related to the business ventures in 2004 and, consequently,
amortized fees for 2004 decreased by 65% from 2003.
The increase in research revenues/milestones primarily reflects
increased activity coupled with the timing of the achievement of
milestones.
This excerpt taken from the ELN 6-K filed Oct 27, 2005. Contract Revenue
Contract revenue in the third quarter of 2005 was $10.2 million, a decrease of 34% from the $15.4 million recorded in the third quarter of 2004, principally due to a reduction in research revenue and milestones arising from research and development activities performed by Elan on behalf of third parties. The reduction resulted from, among other things, the timing of milestone receipts, the completion of transitional research and development activities related to certain divested products and the suspension of activity related to Sonata™.
This excerpt taken from the ELN 6-K filed Jul 28, 2005. Contract Revenue
Contract revenue in the second quarter of 2005 was $7.0 million, a decrease of 53% from the $15.0 million recorded in the second quarter of 2004, principally due to a reduction in research revenue and milestones arising from research and development activities performed by Elan on behalf of third parties. The reduction resulted from, among other things, the timing of milestone receipts, the completion of transitional research and development activities related to certain divested products (principally Skelaxin, Zelapar™ and Zonegran) and the suspension of activity related to Sonata™.
This excerpt taken from the ELN 6-K filed Apr 11, 2005. Contract Revenue Research revenue and milestones totaled $74.1 million in 2004 compared to $49.5 million in 2003, an increase of 50%. The increase primarily reflects increased activity coupled with the timing of the achievement of milestones, principally related to the milestone payments of $14.0 million (2003: $Nil) for Tysabri from Biogen Idec. | EXCERPTS ON THIS PAGE:
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||
